Opioid abuse among pregnant women has reached epidemic proportions and has influenced maternal and child health policy at the federal, state, and local levels. As a result, we review the current state of opioid use in pregnancy and evaluate recent legislative and health policy initiatives designed to combat opioid addiction in pregnancy. We emphasize the importance of safe and responsible opioid-prescribing practices, expanding the availability and accessibility of medication-assisted treatment and standardizing care for neonates at risk of neonatal abstinence syndrome. Efforts to penalize pregnant women and negative consequences for disclosing substance use to health care providers are harmful and may prevent women from seeking prenatal care and other beneficial health care services during pregnancy. Instead, health care providers should advocate for health policy informed by scientific research and evidence-based practice to reduce the burden of prenatal opioid abuse and optimize outcomes for mothers and their neonates.

(Obstet Gynecol 2016;128:4–10)

DOI: 10.1097/AOG.0000000000001446

The prevalence of opioid use among women of childbearing age has reached epidemic proportions in the United States. Between 2008 and 2012, an average of 39.4% of Medicaid-insured and 27.7% of privately insured women of reproductive age (15–44 years) filled an outpatient prescription for an opioid each year with a greater number in the South and among non-Hispanic white women.1 This escalation has led to a rise in opioid use in pregnancy. In an evaluation of more than 1 million Medicaid enrollees, one of five pregnant women (21.6%) filled a prescription for an opioid and 2.5% received a chronic opioid prescription for greater than 30 days.2 Increases in prescription opioid use among pregnant women have led to a stark increase in the proportion of women needing treatment for abuse. From 1992 to 2012, the proportion of pregnant women admitted to substance abuse treatment facilities who reported a history of prescription opioid abuse increased from 2% to 28%.3

Over the last two decades several factors have led to the rapid increase in the consumption of prescription opioids in the United States. In the early 1990s, concern about undertreating pain led to increased emphasis on measuring and treating pain. In that decade, the American Pain Society introduced pain as “the fifth vital sign” and improved health care provider recognition of pain’s importance in patient outcomes and experience.4 However, this emphasis on pain coupled with pharmaceutical company marketing practices downplaying the addictive potential of opioid pain relievers has led to overprescribing and a notable shift in indications for prescription opioids to include chronic, noncancer pain.

An expanded, socioeconomically and demographically diverse population of patients has become addicted to opioids.5 In the 1960s, more than 80% of patients entering treatment programs for opioid abuse were men living in inner-city, urban areas who used heroin.6 By 2010, the majority of patients entering treatment programs were women, often middle class, living in less urban or rural areas, and more than 90% were white.6 Today, the United States accounts for less
than 5% of the world’s population and more than 80% of the world’s consumption of opioid pain relievers. In 2012, there were 239 million prescriptions written for opioid pain relievers in the United States—more than one for every American adult. Complications from opioid pain reliever use are evident throughout society, highlighted by the fact that opioid-related overdose deaths now outnumber deaths from automobile accidents in the United States.

Increases in prescription opioid abuse have also contributed to a rise in heroin use and overdose. Since 2010, heroin use and overdose deaths have more than tripled in the United States, in part attributable to an increase in heroin’s availability and affordability. In 2007, more than 98% of heroin in the United States was imported from South America, in contrast to the 1980s when the majority of heroin was sourced from Southeast Asia. As a result of proximity and an established drug trafficking infrastructure from cocaine, heroin distribution from Columbia and Mexico led to a significant drop in the price of heroin and a rise in availability. Between 1981 and 2012, the average price per pure gram of heroin dropped from $3,260 to $465. As a result, many patients who begin abusing prescription opioids eventually switch to heroin because it is cheaper, more available, and easier to use intravenously. More than two thirds (66%) of pregnant women on medication-assisted treatment report a history of heroin use, and approximately 63% report a history of intravenous heroin use.

The rising prevalence of opioid use in pregnancy has led to an increase in associated adverse neonatal outcomes such as neonatal abstinence syndrome. Neonatal abstinence syndrome is a drug withdrawal syndrome that opioid-exposed neonates experience shortly after birth. From 2000 to 2012, the number of neonates diagnosed with the syndrome grew nearly fivefold. By 2012, one neonate was born, on average, every 30 minutes in the United States having drug withdrawal, which accounts for an estimated $1.5 billion in health care expenditures. States with the highest rates of opioid-prescribing have the highest rates of neonatal abstinence syndrome and in some communities, neonatal abstinence syndrome admissions represent nearly 50% of all neonatal intensive care unit hospital days. Compared with non-opioid-exposed neonates, those with neonatal abstinence syndrome are more likely to be white, have lower birth weights, respiratory complications, feeding difficulty, and seizures.

**HEALTH POLICY AND OPIOID ABUSE**

Escalating trends in opioid abuse during pregnancy and neonatal abstinence syndrome have captured the attention of policymakers and elected officials at the federal, state, and local levels. Although the majority of recent public policy initiatives are designed to improve the accessibility and affordability of substance abuse treatment services for pregnant women, efforts to criminalize pregnant women who have addiction have been on the rise. In 2014, Tennessee became the first state to prosecute women for assault for the illegal use of a narcotic while pregnant. Although assault charges remain unique, a number of states have taken alternative policy approaches to penalize pregnant women with addiction. For example, the Supreme Courts of Alabama and South Carolina expanded their interpretation of child welfare statutes, originally intended to protect children from illicit drug production and distribution in homes, to allow for prosecution of pregnant women with substance use disorders. In 18 states, substance abuse during pregnancy can now be classified as criminal child abuse and can result in the termination of parental rights.

Efforts to penalize pregnant women or negative consequences for disclosing substance use to health care providers may prevent women from seeking prenatal care and other preventive health care services, alienating vulnerable patients from their health care providers. Instead, health care providers should routinely screen all pregnant women for drug and alcohol use through a comprehensive history and physical evaluation and with validated screening tools such as the “4Ps.” After informed consent and assurance of patient confidentiality, urine drug testing can then be used to detect or confirm suspected substance use.

**ADDITION AS A CHRONIC DISEASE**

The National Institute on Drug Abuse defines addiction as a chronic disease that can be managed and treated successfully. Similar to other chronic disease processes (eg, diabetes, hypertension), the successful treatment of substance use disorders depends on social support, patient–health care provider rapport, and treatment availability. Approximately 40–60% of patients relapse and resume illicit drug use in the first year after discharge from substance abuse treatment programs, which is similar to a 60% relapse rate for adults undergoing treatment for hypertension or asthma. Barriers to treatment in pregnancy created by misguided policy approaches result from a fundamental misunderstanding of the chronicity of addiction and the need to provide ongoing treatment for addiction disorders with both medical and psychosocial interventions.

The standard of care for pregnant woman with opioid use disorder is to initiate medication-assisted treatment with either methadone or buprenorphine.
Opioid use disorder has replaced opioid abuse, dependence, and addiction in pregnancy. Committee Opinion No. 524. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:977–82. Opioid detoxification or withdrawal in pregnancy is not recommended as a result of associations with decreased neonatal birth weight, illicit drug use relapse, and resumption of high-risk behaviors such as intravenous drug use, prostitution, and criminal activity. In contrast, stabilization on medication-assisted treatment during pregnancy minimizes opioid withdrawal, reduces risk-taking behavior, and decreases the acquisition and, thus, the transmission of infectious diseases such as hepatitis C virus and human immunodeficiency virus. Medication-assisted treatment is most effective when used in combination with counseling or behavioral therapy, which is required by 21 states for patients enrolled in medication-assisted treatment programs. As a result, a coordinated team of clinicians including addiction medicine specialists, behavioral health providers, obstetricians and gynecologists, and social services providers should supervise the initiation of medication-assisted treatment in pregnancy.

The recommended medication-assisted treatment for pregnant women with opioid use disorder is methadone. Approximately 1,300 federally licensed methadone treatment facilities across the United States offer medication-assisted treatment options to patients (Box 1). Opioid use disorder has replaced opioid abuse and opioid dependence psychiatric diagnoses in the Diagnostic and Statistical Manual of Mental Disorders (5th Edition) and is defined as a problematic pattern of opioid use resulting in symptoms such as tolerance, withdrawal, craving, or an inability to cut down or control opioid use. Opioid detoxification or withdrawal in pregnancy is not recommended as a result of associations with decreased neonatal birth weight, illicit drug use relapse, and resumption of high-risk behaviors such as intravenous drug use, prostitution, and criminal activity. In contrast, stabilization on medication-assisted treatment during pregnancy minimizes opioid withdrawal, reduces risk-taking behavior, and decreases the acquisition and, thus, the transmission of infectious diseases such as hepatitis C virus and human immunodeficiency virus. Medication-assisted treatment is most effective when used in combination with counseling or behavioral therapy, which is required by 21 states for patients enrolled in medication-assisted treatment programs. As a result, a coordinated team of clinicians including addiction medicine specialists, behavioral health providers, obstetricians and gynecologists, and social services providers should supervise the initiation of medication-assisted treatment in pregnancy.

The recommended medication-assisted treatment for pregnant women with opioid use disorder is methadone. Approximately 1,300 federally licensed methadone treatment facilities across the United States offer medication-assisted treatment options to patients (Box 1). Although protocols differ among treatment programs, methadone inductions often occur in inpatient settings because it is a full opioid receptor agonist and supratherapeutic doses carry the risks of respiratory depression and overdose. Once dose stabilization is achieved, patients continue to receive medication at federally regulated outpatient methadone treatment facilities, which require patients to return each day for supervised dose administration. As a result of federal requirements, many methadone treatment facilities have clinical staff formally trained in addiction medicine, offer on-site individual and group counseling, and are equipped to provide case management and referral services, educational resources, and job training to patients.

In 2002, the U.S. Food and Drug Administration approved buprenorphine, a partial opioid receptor agonist, for the treatment of opioid use disorder. More than 30,000 physicians, from a variety of clinical specialties, are licensed to prescribe buprenorphine in private, office-based settings. As a result of a decreased risk of overdose, buprenorphine inductions can occur in office-based settings and patients self-administer their medication by filling an outpatient buprenorphine prescription. Office-based administration liberates patients from the stigma associated with many methadone treatment facilities and increased flexibility may eliminate barriers for women with work or childcare responsibilities. Moreover, emerging evidence demonstrates superior neonatal outcomes, including shorter treatment duration for neonatal abstinence syndrome for neonates exposed to buprenorphine compared with methadone. Although clinical guidelines are still evolving, candidates for buprenorphine include patients who may have limited access to methadone, who demonstrate an ability to self-administer their medication without

Box 1. American College/Congress of Obstetricians and Gynecologists’ Resources


Box 2. Additional Resources

a concern for diversion, and who have been successfully treated with buprenorphine before pregnancy. Pregnant patients enrolled in methadone treatment programs should not be transitioned to buprenorphine as a result of a risk of precipitated withdrawal. All pregnant patients treated with buprenorphine should be counseled that there is limited data regarding the effect of buprenorphine on infant and child outcomes beyond the neonatal period. Despite the growing availability and popularity of buprenorphine, the number of licensed health care providers who offer services to pregnant women remains unknown.

IMPROVING MEDICATION-ASSISTED TREATMENT AVAILABILITY AND ACCESSIBILITY

State legislative and judicial efforts to criminalize pregnant women who suffer from opioid use disorder have generally not been accompanied by efforts to expand the availability and accessibility of treatment programs for pregnant women. Only 19 states have substance abuse treatment programs specifically designed to treat women during pregnancy and only 12 give pregnant women priority access to existing state-supported programs. Limited treatment accessibility also exacerbates barriers in obtaining treatment for opioid use disorder among pregnant women. In 2013, 20 states did not include methadone on their Medicaid preferred drug lists in contrast to buprenorphine, which is covered by Medicaid in all 50 states. A lack of Medicaid coverage for methadone is a missed opportunity to provide comprehensive drug treatment services for pregnant women. The vast majority of the research demonstrating the effectiveness of medication-assisted treatment to prevent adverse maternal and neonatal outcomes in pregnancy has focused on methadone. Moreover, methadone has also proven to be cost-effective. Over a lifetime, methadone treatment has been estimated to yield $37.72 in benefits for every $1 in cost. Additional limits on Medicaid eligibility and benefits for medication-assisted treatment such as prior authorization, quantity limits, and lifetime treatment limits imposed by states to control costs create additional barriers for patients. Eleven states have a lifetime treatment limit, which restricts the total length of time that an individual can receive a medication, for buprenorphine of 3 years or less, which creates significant challenges to treating the chronic nature of addiction.

It is imperative to ensure adequate access to both methadone and buprenorphine during pregnancy because the most effective treatment for opioid use disorder may differ for each woman. Opioid use history (prescription opioids compared with heroin), addiction severity, social support, and resource availability vary widely among pregnant women and can differentially affect the ability of the two treatments to facilitate recovery. Although buprenorphine’s office-based availability may be more convenient for patients with work and childcare responsibilities, busy office-based health care providers may not be able to adequately address the complex needs of women including screening for intimate partner violence, co-occurring substance use disorders, and psychiatric comorbidities. Moreover, buprenorphine’s partial agonist activity may not suppress illicit opioid use for many pregnant women. Buprenorphine’s partial agonist activity may ineffectively alleviate cravings, provide less euphoria, and may be less satisfying for patients with severe addiction compared with a full agonist such as methadone.

IMPROVING CARE FOR NEONATAL ABSTINENCE SYNDROME

Neonates with neonatal abstinence syndrome are also exposed to treatment variability, resulting in inconsistent outcomes. In 2012, the American Academy of Pediatrics released a policy statement calling for standardizing care for substance-exposed neonates at risk of neonatal abstinence syndrome. Since that time, studies have shown that simple adherence to a single treatment protocol, even more than medication choice, is associated with improved outcomes. Despite attempts to standardize neonatal abstinence syndrome treatment, large gaps remain in our understanding of neonatal abstinence syndrome and its optimal medical treatment. Furthermore, more work is needed to explore the potential positive effect of neonatal abstinence syndrome care delivery models that minimize separation of the mother–infant dyad and that minimize adverse postdischarge outcomes such as readmission.

PROTECTING OUR MOTHERS AND INFANTS

The opioid epidemic has resulted in several funding and legislative initiatives designed to improve health care services for pregnant women and their neonates. In 2011, the White House Office of National Drug Control Policy released a national plan to curb the prescription opioid epidemic titled “Epidemic: Responding to America’s Drug Abuse Crisis.” The plan focuses on four main pillars to combat the epidemic: 1) education of health care providers, parents, children, and the public at large; 2) improving tracking and monitoring of prescribers by bolstering prescription drug
monitoring databases; 3) ensuring proper medication disposal; and 4) enforcement targeting pill mills and doctor shopping. The Substance Abuse and Mental Health Services Administration’s National Center on Substance Abuse and Child Welfare also pledged to provide in-depth technical assistance to six states (Connecticut, Kentucky, Minnesota, New Jersey, Virginia, and West Virginia) to strengthen collaboration across child welfare, addiction treatment, medical providers, early childhood, and education systems to improve the health of pregnant and parenting women with addiction and their neonates.

In February 2015, the Government Accountability Office released a report titled “Prenatal Drug Use and Newborn Health” that highlighted gaps in research and federal programs that provide services to pregnant women with opioid use disorder and neonates with neonatal abstinence syndrome. In response to the release of the Government Accountability Office report, The Protecting Our Infants Act of 2015 was introduced and passed with broad bipartisan support in the U.S. Senate and House of Representatives and was signed into law on November 25, 2015, by President Obama. The law directs the Department of Health and Human Services to conduct a review of programs that coordinate services for pregnant women with opioid use disorder and neonates with neonatal abstinence syndrome, develop a strategy to address research gaps, study and develop guidelines to prevent opioid use disorder and neonatal abstinence syndrome, and provide technical assistance to states that are collecting data through existing surveillance mechanisms. Findings from Protecting Our Infants will provide much needed evidence-based recommendations and fill the gaps in research with respect to 1) the most appropriate treatment for pregnant women with opioid use disorder, 2) the most appropriate treatment and management for neonates with neonatal abstinence syndrome, and 3) the long-term effects of prenatal opioid exposure on children, in the hope of improving the efficiency and effectiveness of health care services for pregnant women with opioid addiction and their children.

DISCUSSION
The American College of Obstetricians and Gynecologists, the American Academy of Pediatrics, and the American Society of Addiction Medicine all must collaborate and coordinate their professional guidelines, advocacy positions, and research endeavors regarding prenatal substance use and neonatal abstinence syndrome to provide clarity and guidance for policymakers on the national, state, and local levels in the midst of this emotionally charged, national epidemic. By partnering in this manner, these professional organizations can play a vital role in supporting health policy efforts to reduce maternal opioid abuse and neonatal abstinence syndrome and oppose punitive legislation against pregnant women and their children. Obstetricians, pediatricians, neonatologists, and addiction medicine specialists should advocate for evidence-based practices in the management and treatment of addiction in pregnancy and create trusting and meaningful relationships with patients. Health care providers play a vital role as gatekeepers to health care services designed to effectively manage opioid addiction such as safe and responsible opioid-prescribing practices, non-judgmental screening of all pregnant patients for opioid use disorder, assistance with referral and enrollment in medication-assisted treatment programs, and thoughtful guidance and counseling regarding neonatal abstinence syndrome. Through coordination and collaboration, stakeholders invested in the health and welfare of women and children can reduce the burden of prenatal opioid abuse.

REFERENCES


28. Substance Abuse and Mental Health Services Administration. Medicaid coverage and financing of medications to treat alcohol and opioid use disorders. HHS Publication No. SMA-14-4854.


